Drug Approval | March 25, 2023
Zydus receives final approval from USFDA for Doxepin Hydrochloride Capsules USP, 150 mg
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation)
Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of US $255 million in the US (IQVIA MAT December 2022).
Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
Marksans' OTC Famotidine Tablets USP are acid reducers
Subscribe To Our Newsletter & Stay Updated
